Search
BeiGene: DLL3/CD3 Bispecific Antibody Recommended for Priority Review
3 week ago /
Read about 0 minute
Author：小编
Taralatamab, a pioneering CD3 bispecific antibody therapy developed leveraging Amgen's advanced HLE-BiTE technology platform, has secured a groundbreaking achievement in the treatment of prevalent solid tumors. In June 2025, the Phase III clinical trial DeLLphi-304, focusing on small cell lung cancer, successfully met its primary endpoint of overall survival. This milestone signifies a significant advancement for CD3 bispecific antibodies and CAR-T therapies in the realm of solid tumor treatment.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
